Gemtuzumab
drugOn this page
Also known as Gemtuzumab component of mylotargHp 67.6
Summary
Gemtuzumab (CHEMBL2108342) is a phase-3 clinical-stage antibody; indicated across 1 condition including acute myeloid leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108342 |
| Name | Gemtuzumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Gemtuzumab, Gemtuzumab component of mylotarg, Hp 67.6, GEMTUZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01041040 | PHASE4 | COMPLETED | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) |
| NCT00136084 | PHASE3 | COMPLETED | Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia |
| NCT00860639 | PHASE3 | COMPLETED | Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk |
| NCT06448013 | PHASE1 | RECRUITING | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: acute myeloid leukemia